Abstract
Support for the use of pharmacologic interventions in the autism spectrum is growing. 8, 9 Although medication can be useful for addressing challenging behaviours sometimes associated with the autism spectrum, 5, 9 it is unclear whether psychoactive drugs are useful to manage the core features of the disorder 7 or to improve quality of life. 10 Supporting evidence is also lacking for treatment of psychiatric comorbidity in the autism spectrum. 11 Nonetheless, autistic individuals commonly receive psychoactive drugs, often in combination, including antipsychotics, antidepressants, psychostimulants, anticonvulsants, mood stabilizers, anxiolytics and sedatives. 12 Although not indicated as per the Canadian product label, only 2 medications, risperidone and aripiprazole, are approved by the FDA for the treatment of aggression and irritability. 6, 9 Moreover, little is known about the safety and effi cacy of psychotropic polypharmacy. 13 A concern regarding psychotropic drug use in the autism spectrum is that it increases with age. Data from Medicaid and commercial health plans reported that 40-71% of autistic children and adolescents use psychotropic medication. [14] [15] [16] [17] [18] Parent surveys from registries 19, 20 report use of psychotropic medications slightly lower (27-35%) . Rates of drug use [14] [15] [16] [18] [19] [20] and polypharmacy 14, 15, 18, 19 increase with age, with 5% of autistic children receiving more psychotropic medication per year of age. 16 An increase in psychotropic drug use with age, from 70-81% over 4.5 years, was also reported for 286 autistic adolescents and youth. 21 Another preoccupying factor is that rates of psychoactive drug use also vary greatly depending on country of origin. Studies from Western Europe suggest more conservative prescription practices. In a UK study based on The Health Improvement Network (THIN), only 29% of autistic individuals were prescribed psychotropic drugs. 22 A German study of autistic individuals using national health insurance data found that 33% used psychopharmacological treatments. 23 These varied rates raise questions about potential under-or over-prescription of psychoactive drugs in the autism spectrum.
Although studied in the United States and Europe, data on the use of psychoactive drugs in Canada is limited. In Quebec, 14.3% of families with young autistic children and over 50% of autistic adolescents fi le claims with the public drug insurance plan. 24 So far, studies documenting drug prescription practices in the autism spectrum are mostly cross-sectional and based on prevalent cases. Studies examining the use of psychoactive drugs over time among newly diagnosed individuals, also referred to as incident cases, may improve our understanding of current prescription practices for children at various developmental stages. Here, we used a population-based cohort design to study psychotropic drug-prescribing patterns after ''ASD'' diagnosis, in a longitudinal fashion. Variations in the use and combinations of psychoactive drugs were evaluated from the year before and up to 5 years after diagnosis, while accounting for age at diagnosis.
METHODS

Data Sources and Study Sample
Data were obtained from the Régie de l'assurance maladie du Québec (RAMQ), which administers public health services for all residents of Quebec, Canada. Demographic data on RAMQ benefi ciaries include age, sex, demographic region and date of death. The RAMQ databases document claims for medical services (outpatient, inpatient and emergency room visits), pharmaceutical services, and ICD-9 (International Classifi cation of Diseases: 9 th revision) diagnostic and procedure codes. [25] [26] [27] The data provided by RAMQ for this study spans from January 1993 to December 2010.
Autistic individuals were identifi ed from the medical services database by an algorithm requiring ≥2 diagnostic codes for ''ASD,'' defi ned as ICD-9 code 299.X (excluding 299.2), recorded in the 12 years between January 1998 and December 2010 (Figure 1 ). We included diagnostic codes repeated at least twice to reduce the risk of misclassifi cation. 18, 28 The cohort entry date was defi ned as the date of the fi rst recorded ''ASD'' diagnostic code. Prevalent cases (individuals diagnosed in the 5 years before cohort entry) and those aged ≥ 26 years at cohort entry were excluded to ensure the study sample only contained incident cases involving children and youth. Individuals not covered by the RAMQ drug insurance plan for the entire year preceding cohort entry were also excluded. Individuals were followed for 5 years after cohort entry, or until death, disenrollment of the RAMQ drug plan, or end of the study period (December 2010).
Psychoactive Medication Use
We further identifi ed individuals receiving at least one psychoactive drug within the year preceding and the 5 years following cohort entry. Use of psychoactive drugs was defi ned as ≥1 psychoactive drug claim in a given year. We determined the psychoactive drug class for the year preceding and the 5 years following cohort entry. Drug classes were categorized according to the American Hospital Formulary System 29 and included anticonvulsants, antipsychotics, antidepressants, anxiolytics and attention-defi cit hyperactivity disorder (ADHD) drugs (stimulants and atomoxetine). The most commonly prescribed molecule for each drug class was identifi ed for the study period.
Demographic and Clinical Characteristics
We recorded gender, age at diagnosis, demographic region, the number of visits to a general practitioner or specialist (pediatrician, neurologist, psychiatrist), number of hospitalizations during the year before cohort entry and length of hospital stay. We also documented the types of non-autistic neuropsychiatric disorders diagnosed within the year preceding cohort entry (ICD-9 295-298; 300-319; 345). These disorders included schizophrenia (ICD-9 295), mood disorders (ICD-9 296; 311), anxiety disorders (ICD-9 300), conduct disorders (ICD-9 312-313), ADHD (ICD-9 314), delays in development (ICD-9 315), intellectual disability (ICD-9 317-319) and epilepsy (ICD-9 345). The characteristics were presented for the entire cohort and stratifi ed by the use / no use of psychoactive drugs within the year preceding the cohort entry. This stratifi cation was employed to separate individuals with a more severe health condition (users of psychoactive drugs) from the others (non-users).
Data Analysis
We stratifi ed the entire cohort by psychoactive drug users and non-users and age subgroup (1-5, 6- Psychoactive polypharmacy was evaluated by calculating the proportion of children who received at least 2 concomitant classes of psychoactive drugs during a minimal period of 90 days for the year prior the cohort entry and over the 5 years of follow-up. The 90-day overlap period was retained since the most stringent defi nition. 30 Sensitivity analyses were done using minimal concomitant periods of 30 and 60 days. Moreover, the analysis with a minimal period of 90 days was replicated for each age group. A gap of 15 days was permitted between the last day of medication supply and the next fi ll date (gap of 7 days for the minimal period of 30 days) to account for imperfect adherence and short inpatient stays. The most common combinations of drug classes in each age group were identifi ed. Trends over time and age group were assessed by a generalized estimating equation (GEE), accounting for gender and calendar year of autism spectrum diagnosis.
Proportions of individuals using psychoactive drugs in the year before the cohort entry and for each of the 5 years following were evaluated overall and for each drug class, according to the age group. Trends over time and age group were assessed by a GEE, accounting for gender and calendar year of ''ASD'' diagnosis.
P-values less than 0.05 were considered statistically signifi cant. Analyses were performed using the Statistical Analysis System Software (version 9.4; SAS Institute, Cary, North Carolina). The study was approved by the Research and Ethics Committee of the University of Montreal.
RESULTS
Demographic and Clinical Characteristics
We identifi ed 2,989 incident cases of ''ASD'', among which 1,069 were psychoactive drug users ( Figure 1 ). The median time between the fi rst and second diagnosis needed to be included in the cohort was 3.3 months. Table 1 presents the demographic and clinical characteristics according to the age group and use/non-use of psychoactive drugs. Overall, the median age at fi rst diagnosis was 6 years (Q1:3, Q3:12), 80.2% were males, and 80.6% had consulted a medical specialist in the year before diagnosis. Psychoactive drug users were twice as likely to visit specialists as non-users. Hospitalizations were rare and of short duration, although adolescents and young adults were hospitalized for longer periods than children. Among the 2,989 ''ASD'' cases, 56.1% of children had been diagnosed with another neuropsychiatric disorder in the year before the cohort entry. Psychoactive drug users consistently presented more neuropsychiatric disorders than non-users. The most frequent disorders were developmental delay for the 1 to 5-year-olds, ADHD for the 6 to 12-year-olds, and anxiety disorders for the adolescents and young adults. Epilepsy and intellectual disability were noticeably more frequent in the older group, especially in psychoactive drug users.
Predictors of Psychoactive Medication Use Before the Cohort Entry
Analyses concerning the determinants of use of psychoactive drugs in the year prior to cohort entry are presented in Table 2 . All neuropsychiatric disorders evaluated, with the exception of delays in development, were associated with a greater probability to receive psychoactive medication. Although not statistically signifi cant, visits to a specialist and hospitalization before cohort entry presented the same trend. Predictors by age group were also explored. However, the limited number of observations for each age category introduced some instability in the logistic regression model (data not shown).
Psychoactive Medication Use Over Time
The proportion of psychoactive drug use increased from the year prior to cohort entry (35.6%) to the 5th year of follow-up (53.2%) ( Table 3 ). In the year prior to cohort entry, medication use was below 7% in the 1-5 age group for every psychoactive drug class, but at the 5th year of follow-up antipsychotics and ADHD medication use reached 17.5% and 21.8%, respectively. In the 6-12 age group, antipsychotics and ADHD medication use were more common in the year prior, ADHD drugs use remained stable during follow-up, whereas antipsychotic use increased to almost one-third of individuals at the 5th year. Among the 13-17, the use of the various drug classes was common at the year prior, with several classes increasing substantially during follow-up. With the exception of ADHD medications, all drug classes were frequently prescribed in the 18-25 group in the year prior and were maintained in the following years. Proportions of ADHD drug use increased in the 1-5 group during the 5 years following cohort entry, were highest in the 6-12, but decreased in the older age groups. Anxiolytic use remained relatively stable in all age groups, whereas proportions use of antipsychotics, anticonvulsants and antidepressants steadily increased across all age groups. Time (from the year prior to the 5th year of follow-up) and age group were signifi cantly associated with the use of the diff erent psychoactive classes (p<0.05), even after adjusting for potential calendar year trends; however, time did not signifi cantly infl uence prescriptions of anxiolytic medication (p=0.31). Results remained consistent when medication class trends were stratifi ed by gender (data not shown). Use of ADHD drugs was higher in males (p<0.0001). Gender also impacted the use of anticonvulsants and anxiolytics.
Methylphenidate was the most prescribed ADHD drug (79.7%). Atypical antipsychotics were the most frequently prescribed antipsychotic (~85% of prescriptions), with risperidone being the most common (43.5%). Valproic acid was the most common anticonvulsant prescribed (36.6%). The most frequently used antidepressants were selective serotonin reuptake inhibitors (SSRIs;~50% of prescriptions), with citalopram (18.2%) being the most common. Lorazepam (38.3%) was the most commonly prescribed anxiolytic.
Polypharmacy
Polypharmacy, defi ned as the concomitant use of 2 diff erent drug classes for an overlapping period of 90 days, increased during the study follow-up period from 9% to 22% (p<0.0001; Figure 2A ). Sensitivity analyses using periods of 30 and 60 days presents similar trends. Psychoactive polypharmacy increased steadily throughout follow-up in children (age groups: 1-5 and 6-12) but seemed to stabilize after 3 years in adolescents (13) (14) (15) (16) (17) and young adults (18-25) ( Figure  2B ). Age and time but not gender signifi cantly aff ected polypharmacy (p<0.0001). In the 2 youngest groups (1-5 and 6-12), the use of an antipsychotic and ADHD drugs was the most common combination during followup. In the 13-17 group, the most common combination was an antipsychotic and anticonvulsant drug in the fi rst years following diagnosis, replaced with an antipsychotic and antidepressant over time. In young adults (18) (19) (20) (21) (22) (23) (24) (25) , the most common drug combination was antipsychotics and anticonvulsants throughout follow-up, closely followed by the antipsychotic and antidepressant combination.
DISCUSSION
This cohort study examined changes in the use of psychoactive drugs over time in newly diagnosed cases of ''ASD'' as provided by Quebec Healthcare database. Overall, 35.8% of our cohort had already received at least one psychoactive drug in the year preceding diagnosis. The use of psychoactive drugs increased to 53.2% after 5 years with an individual's age and time since diagnosis strongly infl uencing the type and combinations of drugs prescribed. This increase in prescriptions was especially noticeable in children.
Psychoactive drug use in autistic children has been mostly investigated by cross-sectional studies examining prevalent cases in a particular time period. Here, we followed a cohort of incident cases for up to 5 years and found that several medications are increasingly prescribed from the time of diagnosis, as children grow up. We also report that many children already receive psychoactive drugs before they are diagnosed as ''ASD,'' especially those diagnosed at a later age. Neurodevelopmental disorders in the year before cohort entry strongly predicted future psychoactive drug use, which aligns with fi ndings from other studies of clinical predictors of psychotropic medication use in autism. 14, 18, 19, 31 Such disorders may refl ect a previous misdiagnosis, a delay in obtaining a formal autism diagnosis or diagnostic substitution. 32 Prescriptions of anticonvulsants, antidepressants and antipsychotics increased in the 5 years following cohort entry and in the years following diagnosis in each group. Previous studies show that age is positively correlated with medication use. 21, 33 Behavioural problems associated with autism may evolve with age, 34, 35 infl uencing the medications that are prescribed at various ages. 21 In our study, the most commonly prescribed drug class varied by age group, which supports this conclusion. This may also suggest that physicians are increasingly willing to prescribe particular classes of psychoactive drugs as patients age. The large increase in prescriptions of anticonvulsants in adolescents and young adults during follow-up may refl ect eff orts to address challenging behaviours in these age groups, despite the absence of seizures. Most autistic adults have no access to specialist services, which may explain their high rate of medication. 36 Diffi culties in accessing adequate alternative treatments and services may be contributing to the increasing reliance on psychoactive medications as autistic children grow older. 21, 36 Polypharmacy was common in the years following diagnosis, with the most common combinations of drug classes varying by age group. The positive correlation between polypharmacy and age is consistent with previous studies. 14, 15, 18, 19, 21 Prescriptions in more than one drug class concomitantly increased in each age group in follow-up. This is worrisome because the risks of side eff ects increase if drugs are used concomitantly due to potential drug-drug interactions, additive adverse drug reactions, and 'medication cascade eff ects' (drugs used to treat the adverse eff ects of other drugs). 13 Guidelines like those developed in the UK and the U.S. currently suggest a pathway for particular pharmacological treatments in the autism spectrum. 5, [37] [38] [39] However, recommendations regarding the monitoring of patients treated with atypical antipsychotics vary 40 and guidelines regarding the treatment of associated co-morbidities are greatly needed. 11 Diff erent countries report wide variations in psychopharmacological prescription patterns. 20 Contributing factors may include variations in clinical guidelines, 20 diff erential access to specialty health care, 41 and/or cultural beliefs. 42 Although direct comparison is limited due to the diff erence in methodology, in our study of incident cases, percentages of psychoactive medication use throughout follow-up (35.6-53.2%) is consistent with those reported in published North American studies based on prevalent cases, (40-71%). [14] [15] [16] [17] [18] Many questions remain concerning the eff ects of long-term psychoactive drug use on overall health, especially in children. Antipsychotics are especially concerning. Sedation and metabolic abnormalities including weight gain, diabetes, and cardiovascular eff ects are clinically relevant adverse eff ects in youth using atypical antipsychotics. 43 Use of these drugs should be limited to individuals with severe impairment or risk of injury. 5, 7 The high rate of antipsychotic prescriptions, especially risperidone, recorded in this study, suggests that this may not be the case.
Other psychoactive drug classes were also frequently prescribed. Most ADHD medications have not been studied in suffi cient depth in autistic individuals, who incidentally may be more sensitive than non-autistic individuals to the side eff ects of these drugs. 37 Regarding antidepressants, the Cochrane collaboration found no evidence of benefi t in an updated systematic review, but some evidence of harm regarding treatment of repetitive behaviours with SSRIs in autistic individuals. 44 Furthermore, a systematic review and meta-analysis study assessing the use of anticonvulsant medications for the treatment of behavioural symptoms in autism found no signifi cant diff erence between medication and placebo. 45 This study provides important data about the prescription of psychoactive medications for a large number of autistic individuals over many years of follow-up, enabling a longitudinal analysis of newly diagnosed cases. Compared to methods such as interviews or questionnaires, using computerized administrative databases in such research avoids recall bias, and allows capturing of drug history, medical services and the natural evolution of the disease over a long period. Nonetheless, our population-based study has some limitations inherent to the analysis of administrative databases. First, the diagnoses of ''ASD'' in the RAMQ database was not cross-validated and cannot identify all cases. The sampling methodology used for this study did not allow for prevalence calculations. A published study using 2010 data from the RAMQ based on ICD-9 code 299.X has reported the prevalence of ''ASD'' to be 0.64% in children 2 to 12 years of age and 0.60% in adolescents. 46 The requirement of 2 or more diagnostic codes in our study would limits the potential for misclassifi cation 28 which is however still possible. Additionally, timing of 1 st ''ASD'' diagnosis by a physician could be diff erent from when this was documented in the RAMQ database, which could impact the identifi cation of incident cases. Interestingly, the exclusion criteria used in this study yielded a young cohort of ''ASD'' cases with a median age at fi rst diagnosis of 6 years, which compares favourably with a published Medicaid study evaluating age of fi rst diagnosis (64.9 months). 47 Furthermore, the codes used for the identifi cation of other neuropsychiatric disorders in the year preceding the index date have also not been cross-validated. However, the classes of medications used during this same time period are in alignment with these diagnoses. Second, information regarding the entire 5 years of follow-up was available for only some individuals. Therefore, our results may not refl ect the entire sample. However, we performed a sensitivity analysis to examine changes in the use of other medical services with universal coverage, such as hospitalization and doctor visits (data not shown) and found that these were consistent between the entire cohort and the subgroup of individuals covered by the RAMQ drug plan. Third, given the database reports fi lled prescriptions alone, drugs dispensed may not accurately refl ect medications taken. Finally, this study excluded individuals with private medical insurance, which may introduce selection bias, as those individuals may use expensive non-drug therapeutic approaches more frequently, leading to diff erential drug use.
CONCLUSION
This study shows that among newly diagnosed autistic children and youth, prescriptions of psychoactive medication and polypharmacy increases over time, and an individual's age and the time since diagnosis strongly infl uences the types and combinations of drugs used. This increase over time is potentially concerning, especially if such medications are used to manage the core features of the autism spectrum or to replace other, potentially inaccessible treatments and services. Further research is needed to understand why clinicians prescribe psychoactive drugs with increasing frequency in the years following an autism spectrum diagnosis. Real-life, long-term effi cacy and safety data on the use of these medications, in combination with or in comparison to other non-pharmacological treatment modalities, is urgently needed.
